Literature DB >> 19204628

Urticaria due to etanercept in a patient with psoriatic arthritis.

Joaquín Borrás-Blasco1, Antonio Gracia-Perez, J Dolores Rosique-Robles, Claudia Nuñez-Cornejo, M D Elvira Casterá, F Javier Abad.   

Abstract

A 50-year-old woman was referred to our emergency room because of urticaria. Eleven days after etanercept therapy was started, the patient developed an urticarial rash of the trunk and face. A diagnosis of generalized urticaria was made. Etanercept treatment was suspended. Treatment was started with methylprednisolone and dexchlorpheniramine. The patient's condition improved and she was discharged. In this case, the most probable cause of urticaria was considered to be etanercept because of the temporal relationship between exposure to the drug and the onset of symptoms. The adverse reaction could be considered probable. Although the overall risk of skin adverse events associated with etanercept appears low, clinicians should be aware of this reaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204628     DOI: 10.1097/SMJ.0b013e31819450e7

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

Review 1.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

2.  Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect.

Authors:  Mukaddes Kavala; Ilkin Zindancı; Zafer Türkoglu; Burçe Can; Emek Kocatürk; Serkan Senol; Filiz Topaloglu
Journal:  Case Rep Dermatol Med       Date:  2013-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.